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data collection is used for the same resource items. Methods: Articles citing 
38 trial-based resource use instruments catalogued in the MRC-funded Database 
of Instruments for Resource Use Measurement (www.DIRUM.org) were identified 
using Google Scholar, ISI Web of Science and Scopus, and screened according to 
resource use measure usage. Data were extracted on: the method of administra-
tion, resources measured, rates of return and the nature of the other methods 
of resource use measurement. Results: A total of 146/1503 citations met the 
screening criteria. Nearly all (143/146) used resource use instruments derived from 
Beecham and Knapp’s Client Service Receipt Inventory. Most instruments relied 
on patient- or proxy-recall (126/146) generally administered during researcher 
interviews. Primary and secondary care usage were the most widely asked items 
(136/146) with 75 using no supplementary supporting data such as from hospital 
notes. Twelve studies compared one or more method of data collection for the 
same resource items with 8 indicating good agreement between medical records 
and patient/carer recall, 1 indicating the greater reliability of case notes and 3 were 
not evaluable. ConClusions: Resource use instruments based on patient recall 
are valuable complements to other methods and essential for certain items (e.g. 
out of pocket costs, non-medical costs). However, there remains inappropriate use 
in circumstances where more objective measures are available.
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objeCtives: Generic drugs provide a safe, effective and affordable alternative to 
medicines whose patent protection has expired. Generics have to meet the same 
quality standards as the innovator drugs; the only substantive difference is the price. 
Generic manufacturers compete ‘on a knife-edge’ of narrow margins of profitability. 
The generic pharmaceutical industry is risky and complex, success depends on the 
number of other generic drug manufacturers on the market, which affects the profit 
margins and volumes that each company could realize. The objective of the current 
study was to develop a model that explains the effect of generic drug entry on price 
competition after patent expiration in the pharmaceutical industry. Methods: 
Innovators and their generics selected from all the chemical entities whose pat-
ents expired from 1999 through 2009. Data were obtained from IMS Health (Market 
Segmentation Report) and National Department of Health (Database of Medicine 
Prices) for the patents’ expiration dates, prices, sales volume, therapeutic group, 
schedule, and dosage forms of drugs in the sample. Results: A year after pat-
ent expiration, the innovators’ products retained an average of 59% of the market 
share; the generic-to-innovator price ratio was at an average of 65%. By the end of 
the first year after patent expiration, an average of 2 generics was registered per 
innovators’ product. ConClusions: Generic entry is commercially driven; it is 
influenced by the market size of the innovator product prior to the expiry of the 
patent protection. Generic penetration is slow, only intensifies after 5 years since 
the loss of patent protection. The price erosion of the innovator product is strongly 
influenced by generic penetration. The cost of drugs in South Africa is not coming 
down fast enough.
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objeCtives: Economic evaluations often ignore the possibility of non-linear 
health care costs when chronic diseases occur in combination. This paper aims 
to quantify the comparative effect of single and multiple chronic diseases on hos-
pital resource use. Methods: Using records of all admissions to public hospitals 
in the state of Victoria, Australia in 2010-2011 we estimate multiple regression 
models of hospital length of stay (and total annual discharges) for combinations 
of 11 chronic diseases. For length of stay we run separate models for same-day 
and overnight stays, adjusting for observed and unobserved characteristics of 
patients. Results: A higher chronic disease count decreases the odds of a same-
day hospitalization (day-case) exponentially while some disease combinations 
increased these odds. Having ischemic heart disease (IHD) & dementia doubled the 
odds of a day-case compared to a patient with dementia only. Among overnight 
stays, having a mental disease had the highest single disease effect on length 
of stay (LOS) – increasing LOS by 3-4 days. Some disease combinations had non-
additive effects (i.e. their combined effect was greater/less than the sum of their 
single disease effects) on LOS while others were additive. The interaction effect in 
a depression-renal failure combination added 3 days to its single disease effects, 
while in cancer-osteoporosis it was -2 days. Disease combinations that produced 
a positive interaction effect were usually unrelated diseases. We found disease 
count to be positively correlated with number of admissions. Having a combina-
tion of diseases was generally found to have a less-than-additive effect on the 
number of admissions. ConClusions: Patients with chronic diseases have a 
resource use pattern that includes longer lengths of stays and more admissions. 
Combinations of unrelated diseases are particularly correlated with longer lengths 
of stay therefore it is the disease and combination type that is associated with 
higher lengths of stay and admitted episodes.
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out for patients who had not been hospitalized within six months prior to index 
AMU admission. Results: In the whole group, total cost for IGI was higher (£207.4, 
95%CI: £94.8-£331.2) with no QALY gain (-0.001, 95%CI: -0.009-0.007); IGI was domi-
nated by standard care (3%-probability of ICER< £30,000/QALY). In the sub-group 
of 209 patients (IGI: 106) without a hospital stay in the previous six months, total 
cost for IGI was lower (-£274.2, 95%CI: -£480.4--£46.3) with non-significant QALY 
gain (0.001, 95%CI: -0.011-0.013), and 49%-probability of IGI being dominant (90%- 
probability of ICER≤ £30,000/QALY). In the whole group (sub-group), inpatient cost 
was lower by £212 (£778), and social care cost was higher (lower) by £220 (£141), 
comparing IGI to standard care. ConClusions: The IGI for high-risk older people 
discharged from AMU was not cost-effective for all patients, but was cost-effective in 
patients without a hospital stay in the previous six months. This suggests targeting 
the intervention is required.
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objeCtives: . To establish the correlation of log mean cost with respect to APACHE 
II score, pre-hospitalization and length of hospital stay, and to determine the intra-
group variance of log mean treatment costs in different parameters. Methods: 
Categorical data was presented as frequencies with percentages and was analyzed 
by Chi-square test, log regression and Pearson correlation. A logarithmic trans-
formation was used for total cost to convert into normal distribution. Geometric 
mean and Geometric SD was used to summarize total cost. One way ANOVA was 
used to compare the mean of log (total cost) across various categorical variables. 
Multiple linear regression was used to find the factors associated with total cost 
of hospitalization of OPP. Correlations was used for measuring the strength of 
linear relationship between total cost and APACHE II score. Results: A significant 
variance in log mean treatment costs was observed in different parameters like 
pseudocholinesterase levels, type of poison consumed, anticholinergics admin-
istered and incidence of intermediate syndrome. A high mean cost was observed 
in patients with a pseudocholinesterase level of less than 2000 and those who 
consumed WHO class Ib pesticide. A cost difference of INR 25,000 was noted in 
patients who developed intermediate syndrome. The APACHE II Score, pre-hos-
pitalization period and length of hospital stay had significant correlation with 
log cost. Among the variables, length of hospitalization had strong correlation 
with log cost (r= 0.673, p< 0.001). For every one-unit increase in pre-hospitalization 
period, APACHE II score and length of hospital stay, the log cost increases by INR 
1.01, 1.27 and 1.5 respectively. ConClusions: High costs of treatment coupled 
with a proportionately great loss of man-days, make OPP an extremely important 
area for pharmacoeconomic evaluation and for framing appropriate policies for 
remedial measures. Hence studies evaluating treatment regimens with respect 
to costs and outcome are highly desirable.
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objeCtives: The demand for intensive care units has risen in the recent years 
as the increasing aged population in all countries and in Turkey. The aim of the 
study is to calculate the average cost of intensive care stay(ICS) and to compare 
the cost with the reimbursement amount depending on a public hospital data 
in Turkey. Methods: The records of ICSed patients from a public hospital in 
Ankara were evaluated retrospectively between November 2011 and January 2012. 
The hospital cost and reimbursement amount were calculated depending on the 
data. Results: A total of 104 patients stayed in the given time line. Four patients 
excluded due to the missing data in files. The average cost of pharmaceuticals, 
medical devices, laboratory, health care and total cost per patient were calculated 
as 1209.16 TL± 492.46, 137.48 TL± 41.08, 422.35 TL± 108.70, 873.10 TL± 247.82 and 
2992.43 TL± 994.06, respectively. The average reimbursement amount per patient 
was calculated as 2846.59 TL± 842.60. The average profit or deficit of the hospital 
were calculated for the 1st,2nd,3rd,4th, 5th,6th, 7th,8th,9-15th,16-29th and 30-51st 
days as 34.90 TL± 49.69, -75.48 TL± 671.39, -23.25 TL± 315.41, 382.80 TL± 368.58, 283.09 
TL± 628.57, -266.13 TL± 612.81, 312.45 TL± 416.11, 118.99 TL± 729.00, -916.58 TL± 
1430.94, -1500.57 TL± 3217.87 and -2054.55 TL± 3204.79, respectively. The profit and 
deficit trend line was calculated with the number of ICS days as “y = -51,889x2 + 
446,98x - 631,73” (y= profit or deficit, x= hospital stay days). ConClusions: It was 
concluded that the average daily cost of ICS increased depending on the length of 
stay. The patients in critical state who needed more ICS days may have caused this. 
On the other hand, it was observed that the fixed daily reimbursement amount is 
inadequate for prolonged ICS. As a result this leads to the deficits of the hospitals 
in the prolonged ICS.
PHP77
review of tHe use of resource use instruments Based on Patient 
recall in relation to otHer metHods of cost estimation
Ridyard C., Linck P., Hughes D.A.
Bangor University, Bangor, UK
objeCtives: Instruments for resource use measurement based on patient-recall 
(e.g. questionnaires, logs and diaries) are used extensively in trial-based economic 
evaluations; sometimes on their own and sometimes alongside other methods 
for estimating costs. The aims were to assess: 1) how resource use instruments 
are used in practice; 2) which items of resource use are based most frequently 
on patient-recall; and 3) how estimates compare if more than one method of 
